Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616764 | 0.81 | SLC18A3 (0.33) | SLC18A3 | |
| Hydrochloric Acid SCHEMBL1617127 | 0.79 | ALDH1A1 (0.32) | SLC18A3 | |
| SCHEMBL2148090 | 0.74 | ALDH1A1 (0.37) | SLC18A3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6607826 | 0.72 | ALDH1A1 (0.40) | SLC18A3MEN1CYP2D6KMT2A | |
| SCHEMBL6120938 | 0.72 | SLC18A3 (0.34) | SLC18A3 | |
| SCHEMBL1891737 | 0.72 | SLC18A3 (0.34) | SLC18A3MEN1KMT2A | |
| SCHEMBL1615657 | 0.69 | MAPT (0.45) | MEN1CYP2D6KMT2ACHRM1 | |
| SCHEMBL4448770 | 0.68 | DPP4 (0.30) | — | |
| SCHEMBL10379765 | 0.67 | — | — | |
| SCHEMBL2148202 | 0.67 | ALDH1A1 (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | SLC18A3 2628/4885CHRM2 3465/4885MEN1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.